Skip to main content
. 2009 Jan 23;27(1):28–32. doi: 10.1159/000167005

Fig. 2.

Fig. 2

In both the SALT-1 and SALT-2 studies, the increase in the average daily area under the curve for serum sodium concentrations by visit from baseline to day 30 and 7-day follow-up was significantly greater in the tolvaptan group than in the placebo group. Used with permission of Szatalowicz et al. [15].